1nhaler has raised £2m to develop a single-use dry powder inhaler (DPI).
Inhalable medicines are used to treat conditions such as asthma, epilepsy, allergies and Parkinson’s, but to date, delivery options have been limited due to user accessibility, cost, performance and impact on the environment.
The funding round was led by Archangels, with support from Dr Yusuf Hamied, British Business Investments and seed investors. Hamied, non-executive chair of Indian pharmaceutical giant Cipla, has pioneered the manufacture of affordable drugs for developing countries.
Read more HERE.
